Uganda: HIV-Aids - Focus On Vulnerable Groups

[Monitor] Sometimes, it feels like the fight against HIV/Aids will never end. Each year, a report is released; it might be one showing what new trends are among those infected, or one stating the new challenges pharmacists are meeting in the struggle to come up with a vaccine. What must be applauded is the determination of those involved to find a cure and a way to reduce the risk people are exposed to. What must be acknowledged though is that there are still many hurdles to jump in the fight.
Source: AllAfrica News: Health and Medicine - Category: African Health Source Type: news

Related Links:

Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Condition:   HIV-1-infection Interventions:   Biological: Vaccine and vedolizumab (Entyvio);   Biological: Placebo vaccine and vedolizumab infusion (Entyvio);   Biological: Placebo vaccine and placebo infusion Sponsors:   French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS);   EuroVacc Foundation;   European AIDS Treatment Group (EATG);   Medical Research Council;   University College London, UK.;  ...
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Background: Very limited data are available on the immunovirological outcomes after 13-valent pneumococcal conjugate vaccine (PCV13) in antiretroviral therapy (ART)-treated patients. The aim of this study was to assess the immune-virological outcomes in HIV-1-infected ART-treated patients on stable virological suppression who underwent pneumococcal conjugate vaccination. Methods: Retrospective, cohort study on ART-treated HIV-1-infected individuals, age at least 18 years, with three consecutive determinations of HIV-RNA less than 50 copies/ml before the administration of PCV13 (baseline) at San Raffaele Hospital and w...
Source: AIDS - Category: Infectious Diseases Tags: CLINICAL SCIENCE Source Type: research
Conclusion: Volunteers showed a sustained high commitment. No long-term safety alert was identified during the postvaccine follow-up. Participating in vaccine trials did not increase risky behaviors for HIV infection. Vaccine-induced seropositivity may persist for more than 23 years after receiving rgp160.
Source: AIDS - Category: Infectious Diseases Tags: EPIDEMIOLOGY AND SOCIAL Source Type: research
Vaccine knowledge and anticipated rates of vaccination even lower for pneumococcal disease
Source: The Doctors Lounge - Oncology - Category: Cancer & Oncology Tags: Cardiology, Endocrinology, Family Medicine, Geriatrics, Gynecology, Infections, AIDS, Internal Medicine, Allergy, Critical Care, Emergency Medicine, Nursing, Oncology, Pathology, Pediatrics, Pharmacy, Pulmonology, Rheumatology, Institutional, Source Type: news
Conclusion Enthusiasm unabated, however, new tenofovir-sparing antiretroviral regimens are becoming popular and might account for a resurgence of OBI in the HIV setting.
Source: European Journal of Gastroenterology and Hepatology - Category: Gastroenterology Tags: Original Articles: Hepatology Source Type: research
CONCLUSIONS The qualification and expansion of communication strategies on sexuality in schools is urgent and essential in HIV and AIDS prevention in adolescence, contrary to the current trend of restricting the discussion of these topics in education policies.RESUMO OBJETIVO Analisar a concep ção de jovens soropositivos sobre como prevenir a infecção pelo HIV. MÉTODOS Estudo qualitativo por meio de entrevistas semiestruturadas com jovens soropositivos cujo diagnóstico foi feito na adolescência havia no máximo 5 anos. Seguimos roteiro semiestruturado contendo dados soc...
Source: Revista de Saude Publica - Category: International Medicine & Public Health Source Type: research
More News: African Health | AIDS Vaccine | Health | HIV AIDS | Vaccines